Sale

Oncology Drugs Market

Oncology Drugs Market Size, Share, Growth, Trends, Forecast: By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy; By Drug Class: Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others; By Indication: Lung Cancer, Others; By Dosage Forms; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Oncology Drugs Market Outlook

The oncology drugs market size was valued at USD 165.9 billion in 2023, driven by the rising prevalence of personalised medicine across the major markets. The market is expected to grow at a CAGR of 13.2% during the forecast period of 2024-2032, with the values likely to rise from USD 187.8 billion in 2024 to USD 506.6 billion by 2032.

 

Oncology Drugs Market Overview

The market demand is primarily driven by the increasing incidence of cancer across the globe. As per the American Cancer Society, cancer is estimated to affect around 1,958,310 new patients in 2023 and lead to 609,820 cancer deaths in the United States. Breast (15%), lung and bronchus (12%), prostate (15%) and colorectal (8%) cancers are likely to account for approximately 50% of the new cancer cases in the region. While most of the cancer deaths can be associated with lung and bronchus (21%), colorectal (9%), pancreas (8%), breast cancer (7%) followed by the rest of the categories that will account for the remaining 55% share. As a result, there has been rising emphasis on early diagnosis, treatment, and preventing tumor recurrence in patients.

 

The current oncology drugs market trends involve rising incidence of drug approvals by the regulatory bodies such as the FDA. The increasing integration of novel technologies such as artificial intelligence and robotics is a major factor in the growing market size. In addition, the healthcare companies are playing a critical role in fueling increased production of oncology drugs in recent times.

 

Increased Drug Approvals by Regulatory Authorities

The oncology drugs market demand is influenced by rising number of clinical trials in the market. In December 2023, Merck, a leading healthcare company spanning across multiple domains, received the FDA approval for their drug belzutifan , developed to treat renal cell carcinoma, a type of kidney cancer. The drug is branded as Welireg and has been approved on the basis of positive data shown from the late-stage trial. With rising enhancements in the drug development process, the incidence of clinical trials has also increased, aiding growth in the market size.

 

Growing Collaborations Amongst Key Players

The rising convergence of software and related services into the drug development process is expected to boost the oncology drugs market growth. Several companies are coming together to offer accelerated drug manufacturing. In June 2023, Simulations  Plus, a simulation software and services provider, acquired Immunetrics, Inc. to provide QSP (quantitative systems pharmacology). QSP is a flourishing field in pharmaceutical development as it explains the mechanisms behind disease progression and quantify pharmacodynamics as well as pharmacokinetics using mathematical operations.

 

In April 2023, Germany based BioNTech signed a partnership with a Chinese biotech company called DualityBio to co-manufacture and commercialize two new cancer antibody drug candidates. The new drugs include DB-1303 and DB-1311, which will be used as a combination therapy for treating solid tumors. DB-1303 (DualityBio’s lead candidate) has also achieved Fast Track designation from the U.S. FDA and is currently in second of three phases of clinical development. The market is experiencing increasing collaborations on a global level, which is expected to fuel market value in upcoming years.

 

Integration of Artificial Intelligence to Offer Personalized Treatment

The oncology drugs market landscape has been subjected to multiple changes with the advent of new technologies. As cancer indications differ from patient to patient, offering personalized treatment to those affected has been a key area of interest among researchers. In such cases, immunotherapy has emerged as an effective therapeutic alternative. In September 2023, an Oxford based biotech company, Etcembly  developed a generative artificial intelligence enabled immunotherapy drug known as T-cell engagers. These drugs work by bringing white blood cells closer to cancerous cells to facilitate cell death. They are created using a generative AI engine called EMLy, with a vision to activate the body’s natural defense system.

 

Another artificial intelligence designed cancer drug ISM3091 , which has been developed by Insilico Medicine, inhibits DNA repair of the cancerous cells. The new technology analyses multi-omics datasets for potential drugs and detects molecules that block them. This drug technology is expected to receive USD 80 million from Exelixis in the final quarter of 2023.

 

Meeting Global Demand for Oncology Drugs with New Approach

The oncology drugs market size is anticipated to increase owing to several initiatives related to reduce waste and promote cost savings. In recent times, redispensing unused oral cancer drugs has proved beneficial as a new approach. In November 2023, Netherlands doctors and healthcare p rofessionals conducted the ROAD Study wherein they asked 1071 cancer patients to return their unused oral cancer to the nearby pharmacies. After verifying the quality and shelf life, they were later sold to other patients. Redispensing unused drugs helped in improving affordability and sustainability of cancer treatment. It resulted in an annual saving of USD 680 to USD 1591  per patient. The net waste reduction decreased by 2.4%, indicating that it may be a viable option for cost saving in the forthcoming years as well.

 

Oncology Drugs Market Segmentation

Market Breakup by Therapy Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy

 

Market Breakup by Drug Class

  • Cytotoxic Drugs
  • Alkylating Agents
  • Antimetabolites
  • Others
  • Targeted Drugs
  • Monoclonal Antibodies
  • Others
  • Hormonal Drugs
  • Others

 

Market Breakup by Indication

  • Lung Cancer
  • Stomach Cancer
  • Blood Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Others

 

Market Breakup by Dosage Forms

  • Injection
  • Tablets
  • Others

 

Market Breakup by End User

  • Hospitals and Clinics
  • Cancer Research Centers
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan

 

Oncology Drugs Market Regional Analysis

The United States, with a robust healthcare infrastructure, is anticipated to lead the market in upcoming years. The oncology drugs market share is boosted by the growing research activities in the region, owing to the presence of prominent academic institutions and healthcare companies. In November 2023, researchers at Weill Cornell Medicine led a phase 1 trial for a new radiopharmaceutical drug  ‘225AC-J591’ to treat prostate cancer in men. The radiopharmaceutical is injected and consists of two parts, mainly an antibody called J591, that affects a prostate cancer specific protein.

 

Oncology Drugs Market: Competitor Landscape

In December 2023, Absci Corporation, a leader in producing generative artificial intelligence antibody partnered with AstraZeneca to deliver AI designed antibodies with the help of Absci’s Drug Creation™ platform. It aims at leveraging AstraZeneca’s oncology expertise and Absci’s de novo AI antibody creation platform to create a new antibody therapy in oncology.

 

In December 2023, Pfizer completed the acquisition of Seagen for USD 43 billion. This ADC (antibody-drug conjugate) buyout has expanded Pfizer’s oncology pipeline to approximately 60 programs. As per Pfizer’s report, the recent buyout is expected to generate a USD 3.1 billion revenue in 2024. In recent times, ADC therapy developing companies have become a key area of attention amongst leading market players as they emphasize on enhancing the quality of oncological drugs present in the market.

 

The key features of the oncology drugs market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies added in the report are as follows:

 

  • F. Hoffmann-La Roche Ltd.
  • Novartis International AG
  • Pfizer Inc
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • AbbVie Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Celgene Corporation (Now part of Bristol-Myers Squibb)
  • Gilead Sciences, Inc.
  • Merck KGaA
  • Ipsen S.A.

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapy Type
  • Drug Class
  • Indications
  • Dosage Forms
  • End User
  • Region
Breakup by Therapy Type
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy
Breakup by Drug Class
  • Cytotoxic Drugs
  • Targeted Drugs
  • Hormonal Drugs
  • Others
Breakup by Indications
  • Lung Cancer
  • Stomach Cancer
  • Blood Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Others
Breakup by Dosage Forms
  • Injection
  • Tablets
  • Others
Breakup by End User
  • Hospitals and Clinics
  • Cancer Research Centers
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd.
  • Novartis International AG
  • Pfizer Inc
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • AbbVie Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Celgene Corporation (Now part of Bristol-Myers Squibb)
  • Gilead Sciences, Inc.
  • Merck KGaA
  • Ipsen S.A.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology
2    Executive Summary
3    Cancer Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Cancer Epidemiology Analysis – 7MM
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Cancer Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Cancer Epidemiology Forecast (2017-2032)
        5.3.1    Germany Cancer Epidemiology Forecast (2017-2032)
        5.3.2    France Cancer Epidemiology Forecast (2017-2032)
        5.3.3    Italy Cancer Epidemiology Forecast (2017-2032)
        5.3.4    Spain Cancer Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Cancer Epidemiology Forecast (2017-2032)
    5.4    Japan Cancer Epidemiology Forecast (2017-2032)
6    Oncology Drugs Market Overview – 7MM
    6.1    Oncology Drugs Market Historical Value (2017-2023) 
    6.2    Oncology Drugs Market Forecast Value (2024-2032)
7     Oncology Drugs Market Landscape-7MM
    7.1     Oncology Drugs Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2     Oncology Drugs Product Landscape
        7.2.1    Analysis by Therapy Type
        7.2.2    Analysis by Indication
        7.2.3    Analysis by Dosage Forms
        7.2.4    Analysis by End User
8    Cancer Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10     Oncology Drugs Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model 
    10.4    Key Demand Indicators
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends 
    10.7    Value Chain Analysis
11     Oncology Drugs Market Segmentation -7MM
    11.1     Oncology Drugs Market by Therapy Type
        11.1.1    Market Overview 
        11.1.2    Chemotherapy 
        11.1.3    Targeted Therapy 
        11.1.4    Immunotherapy 
        11.1.5    Hormonal Therapy
    11.2    Oncology Drugs Market by Drug Class
        11.2.1    Market Overview 
        11.2.2    Cytotoxic Drugs
            1.1.1.1    Alkylating Agents
            1.1.1.2    Antimetabolites
            1.1.1.3    Others
        11.2.3    Targeted Drugs
            1.1.1.4    Monoclonal Antibodies
            1.1.1.5    Others
        11.2.4    Hormonal Drugs
        11.2.5    Others
    11.3    Oncology Drugs Market by Indication
        11.3.1    Market Overview 
        11.3.2    Lung Cancer 
        11.3.3    Stomach Cancer 
        11.3.4    Blood Cancer 
        11.3.5    Colorectal Cancer 
        11.3.6    Breast Cancer 
        11.3.7    Prostate Cancer 
        11.3.8    Bladder Cancer 
        11.3.9    Others 
    11.4    Oncology Drugs Market by Dosage Forms
        11.4.1    Market Overview
        11.4.2    Injection
        11.4.3    Tablets
        11.4.4    Others
    11.5    Oncology Drugs Market by End User
        11.5.1    Market Overview
        11.5.2    Hospitals and Clinics
        11.5.3    Cancer Research Centres
        11.5.4    Ambulatory Surgical Centres
        11.5.5    Specialty Clinics
        11.5.6    Retail Pharmacies
        11.5.7    Online Pharmacies
    11.6     Oncology Drugs Market by Region
        11.6.1    Market Overview
        11.6.2    United States
        11.6.3    EU-4 and the United Kingdom
            11.6.3.1    Germany
            11.6.3.2    France
            11.6.3.3    Italy
            11.6.3.4    Spain
            11.6.3.5    United Kingdom    
        11.6.4    Japan
12    United States Oncology Drugs Market
    12.1    Oncology Drugs Market Historical Value (2017-2023) 
    12.2    Oncology Drugs Market Forecast Value (2024-2032)
    12.3    Oncology Drugs Market by Therapy Type
    12.4    Oncology Drugs Market by Indication Type
13    EU-4 and United Kingdom Oncology Drugs Market
    13.1    Oncology Drugs Market Historical Value (2017-2023) 
    13.2    Oncology Drugs Market Forecast Value (2024-2032)
    13.3    Germany Oncology Drugs Market Overview
        13.3.1    Oncology Drugs Market by Therapy Type
        13.3.2    Oncology Drugs Market by Indication Type
    13.4    France Oncology Drugs Market Overview
        13.4.1    Oncology Drugs Market by Therapy Type
        13.4.2    Oncology Drugs Market by Indication Type
    13.5    Italy Oncology Drugs Market Overview
        13.5.1    Oncology Drugs Market by Therapy Type
        13.5.2    Oncology Drugs Market by Indication Type
    13.6    Spain Oncology Drugs Market Overview
        13.6.1    Oncology Drugs Market by Therapy Type
        13.6.2    Oncology Drugs Market by Indication Type
    13.7    United Kingdom Oncology Drugs Market Overview
        13.7.1    Oncology Drugs Market by Therapy Type
        13.7.2    Oncology Drugs Market by Indication Type
14    Japan Oncology Drugs Market
    14.1    Oncology Drugs Market Historical Value (2017-2023) 
    14.2    Oncology Drugs Market Forecast Value (2024-2032)
        14.2.1    Oncology Drugs Market by Therapy Type
        14.2.2    Oncology Drugs Market by Indication Type
15    Patent Analysis
    15.1    Analysis by Type of Patent
    15.2    Analysis by Publication year
    15.3    Analysis by Issuing Authority
    15.4    Analysis by Patent Age
    15.5    Analysis by CPC Analysis
    15.6    Analysis by Patent Valuation 
    15.7    Analysis by Key Players
16    Grants Analysis
    16.1    Analysis by Year
    16.2    Analysis by Amount Awarded
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Grant Application
    16.5    Analysis by Funding Institute
    16.6    Analysis by NIH Departments
    16.7    Analysis by Recipient Organization 
17    Clinical Trials Analysis
    17.1    Analysis by Trial Registration Year
    17.2    Analysis by Trial Status
    17.3    Analysis by Trial Phase
    17.4    Analysis by Therapeutic Area
    17.5    Analysis by Geography
18    Funding and Investment Analysis
    18.1    Analysis by Funding Instances
    18.2    Analysis by Type of Funding
    18.3    Analysis by Funding Amount
    18.4    Analysis by Leading Players
    18.5    Analysis by Leading Investors
    18.6    Analysis by Geography
19    Partnership and Collaborations Analysis
    19.1    Analysis by Partnership Instances
    19.2    Analysis by Type of Partnership
    19.3    Analysis by Leading Players
    19.4    Analysis by Geography
20    Supplier Landscape
    20.1    F. Hoffmann-La Roche Ltd.
        20.1.1    Financial Analysis
        20.1.2    Product Portfolio
        20.1.3    Demographic Reach and Achievements
        20.1.4    Mergers and Acquisition
        20.1.5    Certifications
    20.2    Novartis International AG
        20.2.1    Financial Analysis
        20.2.2    Product Portfolio
        20.2.3    Demographic Reach and Achievements
        20.2.4    Mergers and Acquisition
        20.2.5    Certifications
    20.3    Pfizer Inc
        20.3.1    Financial Analysis
        20.3.2    Product Portfolio
        20.3.3    Demographic Reach and Achievements
        20.3.4    Mergers and Acquisition
        20.3.5    Certifications
    20.4    Merck & Co., Inc.
        20.4.1    Financial Analysis
        20.4.2    Product Portfolio
        20.4.3    Demographic Reach and Achievements
        20.4.4    Mergers and Acquisition
        20.4.5    Certifications
    20.5    AstraZeneca PLC
        20.5.1    Financial Analysis
        20.5.2    Product Portfolio
        20.5.3    Demographic Reach and Achievements
        20.5.4    Mergers and Acquisition
        20.5.5    Certifications
    20.6    Bristol-Myers Squibb Company
        20.6.1    Financial Analysis
        20.6.2    Product Portfolio
        20.6.3    Demographic Reach and Achievements
        20.6.4    Mergers and Acquisition
        20.6.5    Certifications
     20.7    Johnson & Johnson
        20.7.1    Financial Analysis
        20.7.2    Product Portfolio
        20.7.3    Demographic Reach and Achievements
        20.7.4    Mergers and Acquisition
        20.7.5    Certifications
    20.8    AbbVie Inc.
        20.8.1    Financial Analysis
        20.8.2    Product Portfolio
        20.8.3    Demographic Reach and Achievements
        20.8.4    Mergers and Acquisition
        20.8.5    Certifications
    20.9    Sanofi 
        20.9.1    Financial Analysis     
        20.9.2    Product Portfolio
        20.9.3    Demographic Reach and Achievements
        20.9.4    Mergers and Acquisition
        20.9.5    Certifications
    20.10    Takeda Pharmaceutical Company Limited
        20.10.1    Financial Analysis
        20.10.2    Product Portfolio
        20.10.3    Demographic Reach and Achievements
        20.10.4    Mergers and Acquisition
        20.10.5    Certifications
    20.11    Eli Lilly and Company
        20.11.1    Financial Analysis
        20.11.2    Product Portfolio
        20.11.3    Demographic Reach and Achievements
        20.11.4    Mergers and Acquisition
        20.11.5    Certifications
    20.12    Celgene Corporation (Now part of Bristol-Myers Squibb)
        20.12.1    Financial Analysis
        20.12.2    Product Portfolio
        20.12.3    Demographic Reach and Achievements
        20.12.4    Mergers and Acquisition
        20.12.5    Certifications
    20.13    Gilead Sciences, Inc.
        20.13.1    Financial Analysis
        20.13.2    Product Portfolio
        20.13.3    Demographic Reach and Achievements
        20.13.4    Mergers and Acquisition
        20.13.5    Certifications
    20.14    Merck KGaA
        20.14.1    Financial Analysis
        20.14.2    Product Portfolio
        20.14.3    Demographic Reach and Achievements
        20.14.4    Mergers and Acquisition
        20.14.5    Certifications
    20.15    Ipsen S.A.
        20.15.1    Financial Analysis
        20.15.2    Product Portfolio
        20.15.3    Demographic Reach and Achievements
        20.15.4    Mergers and Acquisition
        20.15.5    Certifications
21     Oncology Drugs Market - Distribution Model (Additional Insight)
    21.1    Overview 
    21.2    Potential Distributors 
    21.3    Key Parameters for Distribution Partner Assessment 
22    Key Opinion Leaders (KOL) Insights (Additional Insight)
23    Company Competitiveness Analysis (Additional Insight)

    23.1    Very Small Companies
    23.2    Small Companies
    23.3    Mid-Sized Companies
    23.4    Large Companies
    23.5    Very Large Companies
24    Payment Methods (Additional Insight)
    24.1    Government Funded
    24.2    Private Insurance
    24.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 165.9 billion in 2023 driven by increasing preference for personalised medicine across the major markets.

The market is anticipated to grow at a CAGR of 13.2% during the forecast period of 2024-2032, likely to reach a market value of USD 187.8 billion by 2032.

The market demand is driven by increasing incidence of cancer cases, increasing investments to offer personalised treatment options to patients and rising disposable incomes across the major markets.

The rising integration of artificial intelligence into making improved drug solutions is a major market trend. In September 2023, an Oxford based biotech company, Etcembly developed a generative artificial intelligence generated immunotherapy drug known as T-cell engagers. They were created with the help of an AI engine called EMLy and worked by bringing white blood cells closer to cancerous cells to facilitate cell death.

Based on therapy types, the market is divided into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy.

It includes lung cancer, stomach cancer, blood cancer, colorectal cancer, breast cancer, prostate cancer, bladder cancer and others.

It is primarily divided into cytotoxic drugs, targeted drugs, hormonal drugs and others. cytotoxic drugs are further divided into alkylating agents, antimetabolites and others, while targeted drugs are segmented into monoclonal antibodies and others.

It can be injections, tablets, and others.

Major end users include hospitals and clinics, cancer research centers, ambulatory surgical centers, specialty clinics, retail pharmacies and online pharmacies.

The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.

Key players involved in the market are F. Hoffmann-La Roche Ltd., Novartis International AG, Pfizer Inc., Merck & Co., Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Sanofi, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Celgene Corporation (now part of Bristol-Myers Squibb), Gilead Sciences, Inc., Merck KGaA and Ipsen S.A.

Purchase Full Report

Mini Report

$ 3332     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 6110     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8332     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9999     $8999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER